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Abstract
BACKGROUND: Fibrinogen is a risk factor for coronary heart disease (CHD), which is an acute-phase protein that 
is released when inflammation occurs. Fibrinogen is an essential component in the coagulation cascade and affects 
hemostasis, hemorheology, platelet aggregation, and endothelial function. D-dimers are inevitable products of fibrin 
degradation that results from thrombin activation; XIII activated factors and plasmin.
AIM: This study was aimed to explore the accuracy of the fibrinogen/D-dimer ratio in predicting the slow flow 
phenomenon in CHD.
METHODS: The study design is a diagnostic test with a cross-sectional design to assess the accuracy of the 
fibrinogen/d-dimer ratio in predicting coronary slow flow phenomenon (CSFP) in CHD. The study was conducted 
at the Department of Internal Medicine, Faculty of Medicine, Dr. Moh Hoesin Hospital, Palembang, Indonesia. The 
independent variables in this study were serum fibrinogen and D-dimer levels. Meanwhile, the dependent variable 
is sufferers of CHD with CSFP and regular flow. All data obtained from this study were analyzed using the SPSS 
version 20.0 for Windows program with a 95% confidence limit.
RESULTS: This study showed that there was no difference in levels of fibrinogen and D-dimer in groups with CSFP 
and regular flow. Fibrinogen and D-dimer do not play a significant role in the CSFP process. The various etiological 
parts of this possible disorder still need further exploration and detail, ranging from the role of the renin-angiotensin-
aldosterone system, the function of the autonomic nervous system, to the position of other endothelial factors.
CONCLUSION: This study proves that fibrinogen has specific but not sensitive predictors of CSFP. The d-dimer 
value is also not accurate as a CSFP predictor. This study demonstrates that the fibrinogen / d-dimer ratio is not 
precise as a predictor of CSFP events.
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Introduction
Coronary slow flow phenomenon (CSFP) 
is the presence of slow flow in one or more coronary 
artery branching vessels that are seen during contrast 
angiographic actions. There are differences in defining 
CSFP; it has been reported that the range of events 
is 1–7% in the angiographic series and up to 5% in 
cases of an acute coronary syndrome (ACS) [1], [2]. 
There are two methods of measuring the slow flow 
phenomenon [2]. The first method is thrombolysis 
in myocardial infarction (TIMI) flow grade from 
contrast scores ranging from TIMI 0 (no flow), TIMI 1 
(penetration without perfusion), TIMI 2 (flow, including 
delayed filling), and TIMI 3 (normal flow, opacification 
of distal vessels in <3 s). The second method is the 
corrected TIMI frame count, which is the number of 
frames needed by contrast material to reach a specific 
distal coronary artery point with a standard range of 21 
± 3.5 [1], [3].
Patients generally experience recurrent chest 
pain, which occurs in resting conditions (80%), and 
around 20% require emergency treatment. This condition 
may cause arrhythmia and sudden cardiac death. CSFP 
is considered to be an early phase of atherosclerosis 
involving both small arteries and epicardial arteries, so 
that management is essential to prevent heart failure in 
patients [2], [3]. The endothelium plays a critical role in the 
regulation of vascular pressure, platelet activity, smooth 
muscle proliferation vascular, and plays a role in the 
initiation of the formation of atherosclerosis. Therefore, 
endothelium dysfunction is believed to be one of the 
causes of CSFP coronary artery heart conditions [4].
Fibrinogen is an essential component in 
the coagulation cascade and affects hemostasis, 
hemorheology, platelet aggregation, and endothelial 
function [5], [6]. In the other hand, D-dimers are 
inevitable products of fibrin degradation that results from 
thrombin activation; XIII activated factors and plasmin. 
The presence of D-dimer in plasma is an indication 
of thrombus formation. Measurement of D-dimers, 
markers of thrombosis and hypercoagulation, the 
value of D-dimers can be associated with the amount 
of fibrin formation [7], [8]. Fibrinogen and D-dimers are 
believed to play a role in the pathogenesis of coronary 
heart disease (CHD), namely atherogenesis, platelet 
aggregation, and platelet formation [5], [6].
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However, not all countries or health services 
have highly developed angiography facilities and 
services; some other methods of measuring and 
coordinating the coronary blood flow are needed. 
This study is expected to analyze the accuracy of the 
fibrinogen/D-dimer ratio as a predictor for CSFP in 
patients with heart disease.
Methods
The study design is a diagnostic test with a 
cross-sectional design to assess the accuracy of the 
fibrinogen/d-dimer ratio in predicting CSFP in CHD. The 
study was conducted at Catheterization Laboratory in Dr. 
Moh Hoesin Hospital, Palembang, Indonesia. Submission 
of subjects was conducted from March 1, 2020, to March 
30, 2020. The ethics committee approved this study of 
the Faculty of Medicine of Universitas Sriwijaya with 
registration number 188/kptfkunsri-rsmh/2020.
The subjects were 45 patients who underwent 
diagnostic and therapeutic measures in Dr. Moh Hoesin 
Hospital, Palembang, Indonesia, which meet the inclusion 
and exclusion criteria. The inclusion criteria are all 
patients with CHD who has diagnosed by a cardiologist; 
the patient has ECG changes such as ST-elevation or 
depression, patient aged between 30 and 80 years old 
and willing to participate in research and signed informed 
consent. Exclusion criteria were patients with chronic 
kidney disease and hepatitis, patients with malignant 
diseases, patients with infectious diseases, experiencing 
acute myocardial infarction attacks, pregnant and 
breastfeeding, currently using anticoagulant drugs.
The independent variables in this study were 
serum fibrinogen and D-dimer levels. Meanwhile, the 
dependent variable is sufferers of CHD with CSFP and 
regular flow. The confounding factors in this study are 
gender, obesity, smoking history, diabetes mellitus, 
hypertension, and dyslipidemia.
All data obtained from this study were analyzed 
using the SPSS version 20.0 for Windows program 
with a 95% confidence limit. Descriptive data analysis 
of categorical variables is presented in numbers and 
proportions. Hypothesis testing for categorical unpaired 
variables is performed using the Chi-square test; if the 
Chi-square test requirements are not met, Fisher’s exact 
test performs it. Descriptive data analysis of numerical 
variables with normal distribution is presented in the 
form of mean + standard deviation, analysis of numerical 
descriptive data with abnormal distribution in the form of 
the median (minimum value-maximum value).
Assessing data with normal distribution or 
abnormal distribution can be descriptive with variance 
or analytical coefficient with Shapiro–Wilk. Analysis of 
normally distributed data using unpaired t-test, whereas 
if the data are not generally distributed with Mann–
Whitney. Statistical tests to prove the diagnostic value of 
fibrinogen/d-dimer ratio as a prediction of the occurrence 
of “slow-flow” in CHD contains several quantities such as 
sensitivity, specificity, possible, probable ratio, probable 
negative ratio, positive predictive value, and negative 
predictive value. Several variables were also performed 
multivariate analysis using logistic regression.
Results
Table 1 shows that confounding variables of 
age, sex, smoking history, history of diabetes mellitus, 
history of hypertension, history of heart disease, history 
of dyslipidemia, and BMI did not differ significantly 
between groups of patients who had CSFP and regular 
flow groups.
Table 1 shows that the levels of fibrinogen, 
d-dimer, and fibrinogen/d-dimer ratio did not show 
any significant difference between the CSFP group 
and the normal flow group, p > 0.05. The validity test 
of the fibrinogen/d-dimer ratio to CSFP can be seen 
in Table 1. There were 10 patients (41.7%) with a 
fibrinogen/d-dimer ratio >0.9 showing CSFP and 14 
samples (66.7%) did not show CSFP. At a value of ≤0.9, 
there were 14 samples (66.7%) with CSFP and seven 
samples (33.3%) without CSFP. At a cut-off point of 0.9 
the fibrinogen/d-dimer ratio results in a sensitivity value 
of 41.7%; specificity value 33.3%; positive predictive 
value 41.7%; and negative predictive value 33.3%.
Discussion
Fibrinogen and its metabolites can cause 
endothelial dysfunction through several mechanisms. 
Atherosclerotic lesions contain much fibrin, either in 
the wall of thrombus on the surface of intact plaque 
or spread throughout the plaque. The phenomenon 
is associated with decreased fibrinolytic activity and 
plasminogen concentration. It has been explained 
that fibrin triggers cell proliferation, cell migration, and 
fibronectin-binding, which triggers cell migration and 
adhesion. Fibrinogen and its decomposition products 
mediate the transport of adhesion molecules at the 
endothelial surface and further migration to the intima 
tunica. Decomposition products located in the inner 
layer can trigger mitogenesis and collagen synthesis, 
attract leukocytes, and increase vascular permeability.
Furthermore, fibrin in atherosclerotic plaque 
has a relationship with low-density lipoprotein (LDL) 
and lipid accumulation, which leads to the formation of 
lipid nuclei from atherosclerotic lesions. Furthermore, 
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pro-inflammatory cytokines, such as interleukin 6 (IL-6) 
and tumor necrosis factor-alpha, are produced by 
blood vessels, adipose tissue, and myocardium; this 
increases the synthesis of nitric oxide and leukocyte 
migration into the subendothelial space. These 
cytokines also have a regulatory role, stimulating the 
liver for the synthesis of acute-phase proteins, such 
as fibrinogen, and as a result of inflammatory and pro-
thrombotic reactions. Thus, fibrinogen plays a role in 
the formation of atherosclerotic plaque in the early 
stages of CHD [9], [10], [11], [12], [13], [14], [15].
Atherosclerotic lesions initially arise at 
predilection sites where endothelial cell morphology 
changes due to changes in hemodynamic pressure 
(shear stress and turbulence of blood flow in 
arterial branches) and increased levels of lipids 
and inflammatory factors. Shear stress is directly 
proportional to the viscosity of blood flow, where 
fibrinogen plays a role. With an increase in fibrinogen 
levels contribute to increased hemodynamic pressure 
of blood vessel walls. As a result, endothelial cells 
secrete various adhesion molecules (intercellular 
adhesion molecules-1 [ICAM-1] and vascular cell 
adhesion molecule-1), chemotactic factors (MCP-1), 
and growth factors and loss of anticoagulant function 
due to increased thrombogenicity [10], [11]. Fibrinogen 
binds to endothelial cells through ICAM-1 and settles 
in the subendothelial layer of the extracellular matrix 
at specific concentrations. In the subendothelial layer 
of the extracellular matrix, fibrinogen increases shear 
stress, which induces nuclear activation factor κB 
(NF-κB), which increases the response of endothelial 
cells to disrupt blood flow. Based in vitro studies show 
that fibrinogen induces MCP-1 and IL-8 expression in 
endothelial cells through NF-κB activation. MCP-1 has 
a role in the process of atherogenesis in the recruitment 
of monocytes to the cell wall [12], [13].
Other endothelial cells also express tissue 
factors, which cause conversion of fibrinogen to fibrin 
in cell walls. Fibrinogen stimulates endothelial cells to 
secrete von-Willebrand factor proliferation. Increased 
endothelial cell permeability causes LDL particles to 
spread into the subendothelial cavity. Fibrinogen also 
contributes to the sequestration of LDL and lipoprotein A 
particles, which are atherogenic molecules. The tendency 
of lipoprotein A to accumulate in artery walls depends on 
its binding to fibrin. Oxidized LDL stimulates endothelial 
cells to stimulate adhesion molecules, chemotaxis, and 
growth factors. Molecular interactions between fibrinogen 
and αMβ2 integrin receptors facilitate the accumulation of 
Table 1: Relationships between variables with coronary slow flow phenomenon
Characteristic Coronary slow flow phenomenon
Coronary slow flow phenomenon (+) Coronary slow flow phenomenon (−)
n % n % Total *p
Age
30–39 2 100.0 - - 2 0.489
40–49 6 42.9 8 57.1 14
50–59 7 53.8 6 46.2 13
≥60 9 56.3 7 43.7 16
Total 24 53.3 21 46.7 45
Gender
Male 14 45.2 17 54.8 31
Female 10 71.4 4 28.6 14 0.102
Total 24 53.3 21 46.7 45
Smoking
Yes 5 50.0 5 50.0 10 0.811
No 19 54.5 16 45.7 35
Total 24 53.3 21 46.7 45
Diabetes mellitus
Yes 3 50.0 3 50.0 6 0.810
No 21 53.8 18 46.2 39
Total 24 53.3 21 46.7 45
Hypertension
Yes 13 52.0 12 48,0 25 0.841
No 11 55.0 9 45.0 20
Total 24 53.3 21 46.7 45
Dyslipidemia
Yes 4 66.7 2 33.3 6 0.482
No 20 51.3 19 48.7 39
Total 24 53.3 21 46.7 45
Heart disease
Yes 5 62.5 3 37.5 8 0.567
No 19 51.4 18 48.6 37
Total 24 53.3 21 46.7 45
Body mass index
Normolweight 12 50.0 12 50.0 24 0.478
Overweight 11 55.0 9 45.0 20
Underweight 1 100.0 0 0.0 1
Total 24 53.3 21 46.7 45
Fibrinogen
High 2 40.0 3 60.0 5 0.526
Normal 22 55,0 18 45.0 40
Total 24 53.3 21 46.7 45
d-Dimer
High 10 55.6 8 44.4 18 0.807
Normal 14 51.9 13 48.1 27
Total 24 53.3 21 46.7 45
Fibrinogen/d-dimer ratio
>0.9 10 41.7 % 14 66.7 % 24 0.094
≤0.9 14 66.7 % 7 33.3 % 21
Total 24 53.3 21 46.7 45
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monocytes in cell walls and differentiate into macrophages 
that express toll-like receptors and scavengers receptors. 
Fibrinogen stimulates macrophages to re-produce 
chemokines such as MCP-1 and may play a role in 
the exacerbation of inflammation in cell walls. Oxidized 
LDL also increases thrombogenicity of the lesion by 
stimulating TF production in endothelial cells and 
smooth muscle [16], [17], [18], [19], [20], [21], [22]. The 
process of arterial thrombosis is associated with the 
incidence of acute myocardial infarction. Several risk 
factors for arterial thrombosis strengthen endothelium 
injury [23], [24], [25], [26]. Endothelium in normal 
circumstances, bridging blood vessel wall interactions and 
plays a central role in preventing intraluminal thrombus 
formation [24]. Damage to endothelium can alter the 
above functions and is a predisposition to inflammation, 
thrombosis, vasoconstriction, and vascular muscle 
growth [23], [24]. A ruptured plaque will be covered by 
a thrombus and is a significant cause of the incidence 
of an acute myocardial ischemic syndrome. The results 
of the post mortem examination showed that plaque that 
ruptures more often results in thrombus than endothelial 
erosion. The response to plaque damage involves 
introducing blood from the lumen into the lipid nucleus 
so that there is an intraplaque thrombus [24]. However, 
this study has limitations because it was used a minimal 
number of samples.
This study showed that there was no difference 
in levels of fibrinogen and D-dimer in groups with 
CSFP and normal flow. This shows that fibrinogen 
and D-dimer do not play a significant role in the CSFP 
process. CSFP is indeed still a mystery and a challenge 
for researchers to uncover the pathophysiological 
reasons for this disorder. The various etiological roles of 
this possible disorder still need further exploration and 
detail, ranging from the role of the renin-angiotensin-
aldosterone system, the role of the autonomic nervous 
system, to the role of other endothelial factors.
Conclusion
This study proves that fibrinogen has specific 
but not sensitive predictors of SCFP. The d-dimer value 
is also not accurate as a CSFP predictor. This study 
proves that the fibrinogen/D-dimer ratio is not accurate 
as a predictor of CSFP events.
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